Skip to content

Use of Urinary Neutrophil Gelatinase Associated Lipocalin (uNGAL) in predicting spontaneous bacterial peritonitis in cirrhosis.

Urinary Neutrophil Gelatinase Associated Lipocalin (uNGAL): assessing its role as a biomarker of spontaneous bacterial peritonitis in patients with decompensated cirrhosis and also in the prediction of prognosis.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/09/036783
Enrollment
88
Registered
2021-09-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K703- Alcoholic cirrhosis of liver Health Condition 2: K721- Chronic hepatic failure Health Condition 3: K652- Spontaneous bacterial peritonitis

Interventions

None listed

Sponsors

Taurus Life Sciences Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of decompensated cirrhosis of liver with ascites, with a diagnostic paracentesis done at current admission.

Exclusion criteria

Exclusion criteria: Pre-existing renal disease/CKD, AKI at the time of hospitalization, renal replacement therapy, secondary peritonitis, malignant diseases, prior antibiotic therapy, urinary tract infection

Design outcomes

Primary

MeasureTime frame
Presence of spontaneous bacterial peritonitis and prognosisTimepoint: At time of recruitment and at the end of 30 days (day 0 and day 30)

Secondary

MeasureTime frame
Comparision of urinary NGAL level with renal dysfunctionTimepoint: Day 0;To co-relate uNGAL levels with other ascitic parametersTimepoint: Day 0;TO compare uNGAL and survivalTimepoint: Day 30;To compare uNGAL in SBP and non-SBP groupTimepoint: Day 0

Countries

India

Contacts

Public ContactRaghavendra Rao

Kasturba Medical College, Manipal

ragsmanipal1983@gmail.com9901731924

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026